Esperion Therapeutics, Inc. (ESPR) saw its loss widen to $28.96 million, or $1.29 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $13.12 million, or $0.58 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $29.28 million, compared with an operating loss of $13.23 million in the previous year period.
"Last year, Esperion was focused on building a strong foundation for the development and initiation of our global pivotal Phase 3 clinical development program for bempedoic acid, which the team successfully initiated, including the CLEAR Outcomes cardiovascular outcomes trial," said Tim M. Mayleben, president and chief executive officer of Esperion. "Our focus in 2017 will be on the timely completion of patient enrollment of these LDL-C lowering efficacy studies to enable us to report top-line results by mid-2018. We are encouraged by the early completion of patient enrollment in our long-term safety and tolerability study in January, and remain focused on completing patient enrollment across the remaining global pivotal Phase 3 studies."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
